Richard Kirkner

Rich Kirkner

Contributing Writer

Richard Kirkner is an award-winning journalist and editorial consultant who has specialized in ophthalmology and eye care media for three decades. Based in Philadelphia, his work has been recognized with more than 40 awards for editorial excellence.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma

July 13 2021

Second Sight Gets a Double-Shot Boost Thanks to PO and NIH installment

Up until a few weeks ago, 2021 had been an up-and-down year for retinal prosthesis maker Second Sight Medical Products, but it recently got a ...
Read More

July 6 2021

Samsung Bioepis Brings Heat to Race for Anti-VEGF Biosimilars

South Korea-based Samsung Bioepis Co. has gained another leg up in the race for an anti-VEGF biosimilar to treat retinal diseases in the lucrative US ...
Read More

June 28 2021

Two Steps Forward for Clearside’s SCS Suprachoroidal Platform

The novel platform Clearside Biomedical is developing for delivering drugs to the back of the eye has taken two steps forward in recent weeks, with ...
Read More

May 25 2021

The Four Trends Driving the Digital Space

Money is pouring into digital health at a record clip – $6.7 billion in the first quarter this year, the investment firm Rock Health reports. ...
Read More

May 11 2021

Novartis-Regeneron Dispute Enters a New Phase

If you can’t beat ‘em, try to beat ‘em another way. On the same day the US International Trade Commission (US ITC) dropped a patent ...
Read More

March 31 2021

Aura Biosciences Takes Key Steps to Advance Lead Candidate

With a fresh infusion of capital and a new chief operating officer steeped in regulatory affairs, Aura Biosciences has put key pieces into place to ...
Read More

March 23 2021

Biomedical Informatics Helps Focus Director Dr. Michael Chiang’s Vision for NEI

Michael F. Chiang, MD, who took over as director of the National Eye Institute at the close of 2020, brings a unique background as an ...
Read More

February 23 2021

Ocular Gene Therapy Takes Next Step Beyond Inherited Retinal Disease

Ten years from now, gene therapy for ocular disease will have made the shift from exclusively targeting inherited retinal diseases with very small populations, such ...
Read More

January 12 2021

Lessons learned for Conducting Clinical Trials in Challenging Times

Clinical trials on many levels have been disrupted over the past year, and the current surge can cause further disruption as different regions and cities ...
Read More

December 16 2020

800-pound Gorilla Doesn’t Deter Investors in Ophthalmology Sector

The coronavirus pandemic became the 800-pound gorilla dragging down the economy this year, but 2020 turned out to be a stellar one for investors in ...
Read More

December 8 2020

With Hemera Deal, Janssen Continues Building Out Its Retina Portfolio: Glaucoma on the Horizon

By acquiring the rights to Hemera Biosciences’ gene therapy candidate to treat geographic atrophy – the debilitating end-stage form of dry age-related macular degeneration – ...
Read More

September 15 2020

Innovation Leaders Provide Advice for Retina Start-Ups and the People Who’d Like to Work for Them

Product development in retina is a matter of suitors. That is, people looking for the right product development team to join, and early stage companies ...
Read More